Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...
For Black Americans, the battle with Chronic Myeloid Leukemia is marked by unique survival challenges and treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback